Ignite Creation Date:
2025-12-25 @ 4:15 AM
Ignite Modification Date:
2026-01-15 @ 5:44 PM
Study NCT ID:
NCT02116920
Status:
UNKNOWN
Last Update Posted:
2014-04-17
First Post:
2014-03-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
HPV E6/E7 mRNA Versus HPV DNA as Triage for Cervical Cancer Screening
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002583', 'term': 'Uterine Cervical Neoplasms'}], 'ancestors': [{'id': 'D014594', 'term': 'Uterine Neoplasms'}, {'id': 'D005833', 'term': 'Genital Neoplasms, Female'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D002577', 'term': 'Uterine Cervical Diseases'}, {'id': 'D014591', 'term': 'Uterine Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Cervical Biopsy and Endo-cervical Brushing'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_ONLY'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 1000}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2013-05'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-04', 'completionDateStruct': {'date': '2016-05', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2014-04-15', 'studyFirstSubmitDate': '2014-03-25', 'studyFirstSubmitQcDate': '2014-04-15', 'lastUpdatePostDateStruct': {'date': '2014-04-17', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2014-04-17', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2016-05', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Efficacy Outcome Measure', 'timeFrame': '3 Years', 'description': 'Sensitivity and specificity of HPV DNA test versus E6/E7 mRNA test against gold standard of histopathology confirmed CINs.\n\nAfter the above mentioned time frame, efficacy of 1. HPV DNA Test and 2. E6/E7 mRNA test will be evaluated.\n\nSuch evaluation is not applicable for individual participants.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['CIN', 'HPV DNA', 'mRNA E6/E7', 'CIN triage', 'Cervix Biopsy', 'VIA', 'Cervix Cancer'], 'conditions': ['CIN', 'Cervix Cancer']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://tmc.gov.in', 'label': 'Tata Memorial Centre, Mumbai web site'}]}, 'descriptionModule': {'briefSummary': 'AIM: To develop and standardize a cost effective methodology or algorithm for mRNA E6/E7 for HPV genotypes 16, 18, 31, 33 and 45 as compared to commercially available assays which can be incorporated to triage excess false positives from primary screening for cervical cancers\n\nObjectives:\n\n1. Development and standardization of methodology /algorithm for mRNA E6/E7 testing for HPV genotypes 16, 18, 31, 33 and 45 using Real-time RT-PCR, in cervical samples.\n2. To compare the test performance of this HPV E6/E7 mRNA assay to HPV DNA by HC 2 as secondary screening test, with the reference standard of colposcopy with biopsy, to triage women found positive in primary screening by VIA , in a population based screening for cancer of cervix.\n3. To determine number of false positives in the primary screening test after testing VIA positives with a known high specificity secondary screening test (HPV-DNA HC II ) compared to HPV E6/E7 mRNA testing.\n\nStudy Population: Women in the age group of 30-65 years, who test positive on primary cervical screening test VIA will be enrolled for the proposed diagnostic tests along with reference standard of colposcopy with guided biopsy.\n\nMethodology:\n\nWomen in the age group of 30-65 years undergoing routine cervical cancer screening through hospital ( Preventive Oncology screening clinic) and community based screening programs with abnormal test result using the primary cervical cancer screening test VIA will be recruited in the study. The primary screening test VIA will be administered by application of 5% Acetic Acid to the cervix and visualizing the cervix with the help of a halogen focus lamp. VIA will be considered to be positive if definite acetowhite lesions are visualized close to the squamocolumnar junction.', 'detailedDescription': 'AIM: To develop and standardize a cost effective methodology or algorithm for mRNA E6/E7 for HPV genotypes 16, 18, 31, 33 and 45 as compared to commercially available assays which can be incorporated to triage excess false positives from primary screening for cervical cancers.\n\nObjectives:\n\n1. Development and standardization of methodology /algorithm for mRNA E6/E7 testing for HPV genotypes 16, 18, 31, 33 and 45 using Real-time RT-PCR, in cervical samples.\n2. To compare the test performance of this HPV E6/E7 mRNA assay to HPV DNA by HC 2 as secondary screening test, with the reference standard of colposcopy with biopsy, to triage women found positive in primary screening by VIA , in a population based screening for cancer of cervix.\n3. To determine number of false positives in the primary screening test after testing VIA positives with a known high specificity secondary screening test (HPV-DNA HC II ) compared to HPV E6/E7 mRNA testing.\n\nStudy Population: Women in the age group of 30-65 years, who test positive on primary cervical screening test VIA will be enrolled for the proposed diagnostic tests along with reference standard of colposcopy with guided biopsy.\n\nStudy Site: Women tested positive on primary screening test VIA with referrals for further diagnostic testing at TMH will be enrolled under the study for proposed diagnostic tests along with reference test at tertiary care facility , Dept. of Preventive Oncology, Tata Memorial Hospital in Mumbai.\n\nSample Size To detect statistically significant difference in the test characteristics with 95% confidence limits, 80 % statistical power and alpha =0.05, we require to have around 180 cases of cervical intraepithelial neolplasia in the study.\n\nWith a demonstrated prevalence of around 2% for detecting high grade CIN lesions from our urban and rural community based cervical screening programmes, we need to enroll around 9,000 women from population based cervical cancer screening, to get 180 cases of cervical intraepithelial neolplasia\n\nMethodology:\n\nWomen in the age group of 30-65 years undergoing routine cervical cancer screening through hospital ( Preventive Oncology screening clinic) and community based screening programs with abnormal test result using the primary cervical cancer screening test VIA will be recruited in the study. The primary screening test VIA will be administered by application of 5% Acetic Acid to the cervix and visualizing the cervix with the help of a halogen focus lamp. VIA will be considered to be positive if definite acetowhite lesions are visualized close to the squamocolumnar junction.\n\nCriteria for a positive VIA test are presented below:\n\nPositive VIA test:\n\n1. Opaque, dense, dull, definite, well defined aceto white lesions, touching the squamocolumnar junction or close to the external os.\n2. Strikingly dense acetowhite areas in the columnar epithelium.\n3. Condyloma and Leukoplakia occurring closer to the squamocolumnar junction turning intensely white after application of acetic acid.\n4. Growth on the cervix turning acetowhite.\n\nThe screened women who are tested Screen Positive by the primary screening test VIA will become eligible for recruitment in the study . Screen positive women from the outreach community screening programs will be referred to TMH ( Preventive Oncology screening clinic) for further diagnostic verification.\n\nParticipant Recruitment\n\nThe study participants will be recruited from Hospital ( Preventive Oncology screening clinic) and community based screening programmes in Mumbai. Medical Social Workers will explain the details and the purpose of the study to participants attending the screening clinic. Apparently healthy women in the age group of 30-65 yrs with an intact uterus and no past history of cervical neoplasia will become eligible to participate in the programme. If they are fulfilling the inclusion criteria given above, a written informed consent in the vernacular language (either Hindi or Marathi) will be obtained from the participant and a unique participant identification number will be assigned to the eligible women. Information on socio demographic and reproductive variables will then be collected using a detailed questionnaire.\n\nDemographic, reproductive and sexual history data will be recorded at screening following informed consent..\n\nScreen positive women will be tested for the presence of oncogenic HPV types by Hybrid Capture-II (HC-II) and HPV E6/E7 mRNA testing as diagnostic test. In addition to the above two tests all the screen positive women will also further receive Colposcopy with guided cervical biopsy, the reference gold standard test.\n\nColposcopy will be performed by trained doctors and the colposcopy impression will be noted down along with a punch biopsy from the aceto white area on the cervix detected by the primary screening test VIA. Biopsy specimens will be fixed in 10% formalin and will be processed and reported by the pathology laboratory at the Tata Memorial Centre.\n\nThe reference standard for final disease status will be histology.\n\nPost Test Counseling :\n\nAt the end of all testing procedures post test counseling will be done by the Doctor and Medical Social Worker to explain the significance and the results of the testing procedures performed. The importance of follow up visit to understand the results of HPV/ mRNA E6/E7 and cervical biopsy will be explained to the women.\n\nFollow up and Treatment:\n\nTreatment for opportunistic and reproductive tract infections (RTI) will be provided. Women with High grade lesions (cervical precancers ) HSIL will be recommended to seek treatment with cryotherapy or LEEP (Loop Electrosurgical Excision Procedure) or by cold knife conization at the Tata Memorial Centre Mumbai.\n\nTotal Project Period: Three years:\n\nProposal submission, training, participant recruitment, data collection and analysis, including follow-up of cases at the end of enrollment period'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '30 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Women in the age group of 30 to 65 years (non pregnant and with intact uterus) in urban slum colonies of Mumbai city', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Female between 30-65years of age\n2. Not pregnant by menstrual history\n3. No history of prior treatment for cancer of the cervix\n4. No history of hysterectomy\n5. Healthy enough to undergo a pelvic examination, i.e., not seriously ill with a debilitating condition\n\nExclusion Criteria:\n\n1. Women below and above this age group\n2. Women already screened and detected for cervical precencers and cancers\n3. Women with debilitating condition\n4. Women with Hysterectomy\n5. Women whom are pregnant'}, 'identificationModule': {'nctId': 'NCT02116920', 'acronym': 'PODBT', 'briefTitle': 'HPV E6/E7 mRNA Versus HPV DNA as Triage for Cervical Cancer Screening', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Tata Memorial Hospital'}, 'officialTitle': 'Evaluation of the Diagnostic Performance of HPV E6/E7 mRNA Versus Oncogenic HPV DNA as a Secondary Triage Test for VIA Positive Women in Cervical Cancer Screening Program', 'orgStudyIdInfo': {'id': 'BT/PR6121/SPD/11/1401/2012'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'VIA Positive', 'description': 'Those patients having acetowhite lesion over cervix on visual inspection after application of acetic acid'}]}, 'contactsLocationsModule': {'locations': [{'zip': '400012', 'city': 'Mumbai', 'state': 'Maharashtra', 'status': 'RECRUITING', 'country': 'India', 'contacts': [{'name': 'Sharmila A Pimple, Professor', 'role': 'CONTACT', 'email': 'drsharmilapatil@yahoo.com', 'phone': '+912224154379'}, {'name': 'Tanuja R Teni, SciOffF', 'role': 'CONTACT', 'email': 'tteni@actrec.gov.in', 'phone': '+912227405071'}], 'facility': 'Tata Memorial Hospital', 'geoPoint': {'lat': 19.07283, 'lon': 72.88261}}], 'centralContacts': [{'name': 'Sharmila A Pimple, Professor', 'role': 'CONTACT', 'email': 'drsharmilapatil@yahoo.com', 'phone': '+912224154379'}, {'name': 'Tanuja R Teni, SciOffF', 'role': 'CONTACT', 'email': 'tteni@actrec.gov.in', 'phone': '+912227405071'}], 'overallOfficials': [{'name': 'Sharmila A Pimple, Professor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'TMH, Tata Memorial Centre, Mumbai'}, {'name': 'Tanuja R Teni, SciOfficerF', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'ACTREC, Tata Memorial Centre, Mumbai'}, {'name': 'Gauravi A Mishra, Assoc Prof', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'TMH, Tata Memorial Centra, Mumbai'}, {'name': 'Surendra S Shastri, HOD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'TMH, Tata Memorial Centre, Mumbai'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Tata Memorial Hospital', 'class': 'OTHER_GOV'}, 'collaborators': [{'name': 'Ministry of Science and Technology, India', 'class': 'OTHER_GOV'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor in Preventive Oncology', 'investigatorFullName': 'Dr Sharmila Pimple', 'investigatorAffiliation': 'Tata Memorial Hospital'}}}}